Latest news

• Genfit scraps phase 3 trial of experimental NASH drug

  So far, the success of those efforts has been mixed, with Genfit’s rival Gilead also reporting disappointing late-stage trials of its ASK1 inhibitor selonsertib. ... efforts on our two top priorities: the PBC program and NIS4,” said Pascal Prigent,

• FDA delays decision on Intercept's NASH drug by three months

  Intercept is trailed by Genfit, which is due to release late-phase data on its candidate this quarter, and a large pack of companies with earlier-phase candidates.

• Northsea Therapeutics raises $40m to develop fish oil NASH drug

  French pharma Genfit also has a candidate being studied in NASH in a phase 3 trial, with interim results due in the next few months.

• Genfit presses the gas on NASH with combo trials

  It will enrol patients with suspected NASH and significant to advanced fibrosis, measured using non-invasive diagnostic tools including Genfit’s own NIS4 diagnostic test for NASH. ... Dean Hum. “NASH is a multifaceted cardio-metabolic disease

• Genfit claims FDA breakthrough status for liver disease drug

  Elafibranor has shown promising anticholestatic effects in a Phase 2 clinical trial,” said Pascal Birman, Deputy Chief Medical Officer, Genfit. ... Genfit’s drug has been shown to reduce this however, operating as a dual agonist of the peroxisome